SPEED DUO DIROLEISH K

Informazioni principali

  • Nome commerciale:
  • SPEED DUO DIRO/LEISH K
  • Confezione:
  • Scatola da 6 test
  • Tipo di ricetta:
  • Libera vendita
  • Utilizzare per:
  • Animali
  • Tipo di medicina:
  • Dispositivo medico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • SPEED DUO DIRO/LEISH K
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Cani
  • Area terapeutica:
  • Tutti gli altri prodotti non terapeutici
  • Indicazioni terapeutiche:
  • Diagnosi rapida di anticorpi circolanti specifici nei confronti di Leishmania Infantum e e di antigeni specifici di Dirofilaria immitis su siero, plasma o sangue intero con o senza anticoagulante.
  • Dettagli prodotto:
  • Posologia: Con una pipetta mantenuta in posizione verticale, deporre una goccia del campione in ogni pozzetto. Deporre 5 gocce di REAGENTE in ogni pozzetto. Tempo di lettura: 15 minuti di migrazione.

Altre informazioni

Status

  • Fonte:
  • Ministero della Salute - Italia
  • Numero dell'autorizzazione:
  • 922189182
  • Ultimo aggiornamento:
  • 14-08-2017

Foglio illustrativo: composizione, posologia, indicazioni, interazioni, gravidanza, allattamento, effetti indesiderati, controindicazioni

Speed Duo Diro/Leish K

Q INTERESSE CLINICO

3H KPYVÄSHYPVZP u \U»LSTPU[VZP JOL JVSWPZJL PS JHUL L PS NH[[V

dovuta alla presenza e allo sviluppo nelle arterie polmonari e nel

]LU[YPJVSVKLZ[YVKP\UHÄSHYPHJOPHTH[H+PYVÄSHYPHPTTP[PZ. Viene

[YHZTLZZH KHSSL W\U[\YL KP aHUaHYH 3H KPYVÄSHYPVZP u YLZWVUZHIPSL

KP[VZZLJHYKPHJHZVMÄVJHYKPHJVHMMH[PJHIPSP[nLKPZWULH3HYPJLYJH

degli antigeni circolanti permette di evidenziare l’infestazione da

WHY[L KP ]LYTP HK\S[P VS[YL H L]PKLUaPHYL KPYVÄSHYPVZP VJJ\S[L PU

HZZLUaHKPTPJYVÄSHYPLJPYJVSHU[P KLPJHZP

La leishmaniosi è una malattia del cane dovuta alla proliferazione

nei macrofagi di un parassita chiamato 3LPZOTHUPHPUMHU[\T. Viene

[YHZTLZZH KH \U WPJJVSV KP[[LYV! PS ÅLIV[VTV 3H SLPZOTHUPVZP

u YLZWVUZHIPSL KP ZLNUP JSPUPJP WVSPTVYÄ PU X\HU[V SH YLHaPVUL

immunitaria ha conseguenze variabili sugli organi: abbattimento,

poliadenomegalia, anemia, proteinuria...

3H KPZ[YPI\aPVUL KLSSH KPYVÄSHYPVZP L KLSSH SLPZOTHUPVZP u X\HZP

mondiale ed è legata alla distr buzione del loro vettore. In Europa,

queste due malattie sono molto presenti intorno al bacino del

4LKP[LYYHULV +VWV S»PUMLaPVUL SH KPYVÄSHYPVZP L SH SLPZOTHUPVZP

presentano

fasi

asintomatiche

sublicniche

piuttosto

lunghe,

WLY J\P SH SVYV KPHNUVZP YPZ\S[H KPMÄJPSL ( JH\ZH KLSSH WVZZPIPSL

coesistenza e della gravità di queste malattie, si raccomanda , nelle

zone endemiche, di effettuare uno screening regolare e sistematico

prima di avviare misure di prevenzione.

Q PRINCIPIO

Speed Duo Diro/Leish K è un test qualitativo rapido, basato sul

WYPUJPWPVKLSS»PTT\UVJYVTH[VNYHÄHZ\TLTIYHUHJOLWLYTL[[LKP

mettere in evidenza la presenza di antigeni circolanti di +PYVÄSHYPH

PTTP[PZ e di anticorpi anti-3LPZOTHUPHPUMHU[\Tnel cane.

IT-1

Speed Duo Diro/Leish K

Kit di diagnosi veterinaria

Solo per uso in vitro

7LYVNUP[LZ[uZ\MÄJPLU[LKLWVYYL\UHNVJJPHKLSJHTWPVULZPLYV

WSHZTH V ZHUN\L PU[LYV JVU HU[PJVHN\SHU[L ULS WVaaL[[V KLP

campioni. Una volta deposto il campione, le particelle colorate del

coniugato si legano agli antigeni di +PYVÄSHYPHPTTP[PZWHY[L+PYV

e agli anticorpi anti-3LPZOTHUPHPUMHU[\TWHY[L3LPZO0JVTWSLZZP

coniugato/antigeni

+PYVÄSHYPH

PTTP[PZ

coniugato/anticorpi

anti-3LPZOTHUPHPUMHU[\Tcosì formati migrano per capillarità sulla

TLTIYHUH =LUNVUV X\PUKP JH[[\YH[P KH HU[PJVYWP ZWLJPÄJP HU[P

+PYVÄSHYPH PTTP[PZ L KH HU[PNLUP ZWLJPÄJP KP 3LPZOTHUPH PUMHU[\T

ÄZZH[P Z\SSH TLTIYHUH L MVYTHUV WLY HJJ\T\SV KP WHY[PJLSSL

JVSVYH[L\UHIHUKH[LZ[KPJVSVYLYVZHWHY[LJLU[YHSLKLSSHÄULZ[YH

3»PUZPLTL TPNYH Z\S Z\WWVY[V ÄUV H YHNNP\UNLYL S»LZ[YLTP[n KLSSH

membrana dove le particelle colorate rimanenti formano una banda

di controllo rosa che conferma la corretta esecuzione del test.

Q PROTOCOLLO OPERATIVO

PER OGNI TEST PREVEDERE:

JLSSH[LZ[WPWL[[HTVUV\ZVPSÅHJVULKPYLHNLU[L

Utilizzare i reagenti a temperatura ambiente.

Non mescolare mai reagenti di lotti diversi.

1/ DEPOSITO DEL CAMPIONE:

:PLYVWSHZTHZHUN\LPU[LYVJVUHU[PJVHN\SHU[L,+;(VLWHYPUH!

pipetta

monouso

mantenuta

posizione

verticale,

deporre 1 goccia di campione nel pozzetto dei campioni.

2/ DEPOSITO DEL REAGENTE:

- Aggiungere il reagente subito dopo aver deposto il campione.

4HU[LULYL

ÅHJVUL

YLHNLU[L

WVZPaPVUL

]LY[PJHSL

aggiungerne 5 gocce in ogni pozzetto del campione.

- Se le migrazione non inizia entro 2 minuti, aggiungere altre 2

gocce di reagente nel pozzetto del campione.

IT-2

3/ LETTURA E INTERPRETAZIONE DEI RISULTATI:

Leggere il risultato dopo 15 minuti di migrazione:

- Se il TEST È NEGATIVO compare 1 banda rosa nella

ÄULZ[YHKPSL[[\YHIHUKHKPJVU[YVSSV

- Se il TEST È POSITIVO compaiono 2 bande rosa ben

KPZ[PU[L ULSSH ÄULZ[YH KP SL[[\YH IHUKH [LZ[  IHUKH KP

JVU[YVSSV

3HJVTWHYZHKP\UHIHUKH[LZ[KVWVZVSVTPU\[PKP

migrazione permette di concludere che il test è positivo.

Una colorazione anche molto lieve della striscia test

deve essere considerata come un risultato positivo.

- 3»HZZLUaHKLSSHIHUKHKPJVU[YVSSVZPNUPÄJHJOLPS[LZ[

non è valido.

Q RACCOMANDAZIONI

‹STABILITÀ / CONSERVAZIONE:

mesi

temperatura

ambiente

partire

dalla

data

fabbricazione. La data di scadenza è riportata sul kit e su ogni busta

contenente i test.

-  *VUZLY]HYL H [LTWLYH[\YH HTIPLU[L [YH ‡* L ‡* 5VU

LZWVYYLPS[LZ[H[LTWLYH[\YL[YVWWVLSL]H[LVPUMLYPVYPH*

‹CAMPIONI:

- I campioni di siero, plasma o sangue intero con anticoagulante

devono essere a temperatura ambiente al momento dell’utilizzo.

- *VUZLY]HaPVUL KLP JHTWPVUP ÄUV H  VYL! JVUZLY]HYL ZPLYV

plasma o sangue intero con anticoagulante a temperatura ambiente.

- *VUZLY]HaPVULKLPJHTWPVUPÄUVHVYL!JVUZLY]HYLZPLYVV

WSHZTH[YH‡*L‡*PUMYPNVYPMLYV3HJVUZLY]HaPVULKLSZHUN\L

PU[LYV WLY KP]LYZL VYL [YH ‡* L ‡* W\~ WYV]VJHYL \U»LTVSPZP

IT-3

WHYaPHSLUVU]PZPIPSLHVJJOPVU\KVJOLW\~YLUKLYLWPƒKPMÄJPSL

l’interpretazione del test.

-  6S[YL SL  VYL JVUZLY]HYL ZPLYV L WSHZTH H ‡* 5VU

congelare mai un campione di sangue intero.

‹PRECAUZIONI PER LA MANIPOLAZIONE:

- Per ottenere una migrazione corretta del campione, mettere la

JLSSH[LZ[Z\\UHZ\WLYÄJPLWPHUHLVYPaaVU[HSL

- Per standardizzare la quantità di campione necessaria per

ciascun test, utilizzare esclusivamente le pipette presenti nella

confezione.

- Per deporre correttamente il campione e il reagente, mantenere il

ÅHJVULJVU[HNVJJLKLSYLHNLU[LLSHWPWL[[HPUWVZPaPVUL]LY[PJHSL

‹ ALTRE RACCOMANDAZIONI :

- +\YHU[LS»LZLJ\aPVULKLS[LZ[SHÄULZ[YHKPSL[[\YHW\~TVZ[YHYL

una lieve colorazione rosa, che non ha alcuna conseguenza sulla

qualità del risultato.

- Non mescolare reagenti di lotti diversi.

- Lasciare che i reagenti raggiungano la temperatura ambiente

prima dell’uso.

- Utilizzare una nuova pipetta monouso per ogni test.

Queste raccomandazioni costituiscono solo una guida, in quanto

UVUZPW\~WYL[LUKLYLJOLHSJ\UTL[VKVKPHNUVZ[PJVZPHWYLJPZVHS

 3VZJVWVKPX\LZ[V[LZ[uHP\[HYLPS]L[LYPUHYPVHKPHNUVZ[PJHYL

SH KPYVÄSHYPVZP JHUPUH L SH SLPZOTHUPVZP JHUPUH YPZWL[[P]HTLU[L

mediante rilevamento degli antigeni circolanti di +PYVÄSHYPHPTTP[PZ

e degli anticorpi anti-3LPZOTHUPHPUMHU[\T. L’interpretazione del test

da parte del veterinario dovrà sempre tenere conto dell’anamnesi,

dell’esame clinico dell’animale e del risultato di eventuali altri

LZHTPJVTWSLTLU[HYP3HKPHNUVZPÄUHSLYLZ[H\UHWYLYVNH[P]HKLS

veterinario curante ed è sotto la sua responsabilità

Bio Veto Test

suoi

distributori

possono

essere

ritenuti

responsabili delle conseguenze legate a un utilizzo scorretto o a

un’interpretazione scorretta dei risultati forniti da questo test.

IT-4

Manufactured by / Fabriqué par / Fabricado por / Prodotto da:

BIO VETO TEST

(=,5<,+,964,

3(:,@5,:<94,9-9(5*,

Ref : XPROTODDL-V V1

17-1-2019

SRAM recalls three-speed internal gear hub with coaster brake

SRAM recalls three-speed internal gear hub with coaster brake

The brake can fail, posing a crash or fall hazard to the rider.

Health Canada

12-1-2019

Scientific Opinion on Flavouring Group Evaluation 208 Revision 3 (FGE.208Rev3): consideration of genotoxicity data on alicyclic aldehydes with α,β‐unsaturation in ring/side‐chain and precursors from chemical subgroup 2.2 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 208 Revision 3 (FGE.208Rev3): consideration of genotoxicity data on alicyclic aldehydes with α,β‐unsaturation in ring/side‐chain and precursors from chemical subgroup 2.2 of FGE.19

Published on: Fri, 11 Jan 2019 The EFSA Panel on Food Additives and Flavourings was requested to evaluate the genotoxic potential of flavouring substances from subgroup 2.2 of FGE.19 in the Flavouring Group Evaluation 208 Revision 3 (FGE.208Rev3). In FGE.208Rev1, the Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) evaluated genotoxicity studies on the representative substance p‐mentha‐1,8‐dien‐7‐al [FL‐no: 05.117], which was found to be genotoxic in vivo. The Panel conclu...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from Bacillus subtilis (strain XAS)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from Bacillus subtilis (strain XAS)

Published on: Fri, 11 Jan 2019 The EFSA Panel on Food Additives and Flavourings was requested to evaluate the genotoxic potential of flavouring substances from subgroup 2.2 of FGE.19 in the Flavouring Group Evaluation 208 Revision 3 (FGE.208Rev3). In FGE.208Rev1, the Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) evaluated genotoxicity studies on the representative substance p‐mentha‐1,8‐dien‐7‐al [FL‐no: 05.117], which was found to be genotoxic in vivo. The Panel conclu...

Europe - EFSA - European Food Safety Authority EFSA Journal

10-1-2019

Stanley Black & Decker Canada Corp. recalls DEWALT DWD110 and DWD112 variable speed reversing drills

Stanley Black & Decker Canada Corp. recalls DEWALT DWD110 and DWD112 variable speed reversing drills

The internal wiring of the DEWALT 3/8-inch variable speed reversing drills can come into contact with internal parts, posing a risk of electrical shock.

Health Canada

17-12-2018

Duodenoscope reprocessing

Duodenoscope reprocessing

Update - interim results from FDA surveillance studies

Therapeutic Goods Administration - Australia

10-12-2018

Statement from Jeff Shuren, M.D., J.D., Director of the Center for Devices and Radiological Health, on updated safety communication about rates of duodenoscope contamination from preliminary postmarket data

Statement from Jeff Shuren, M.D., J.D., Director of the Center for Devices and Radiological Health, on updated safety communication about rates of duodenoscope contamination from preliminary postmarket data

FDA provides updates to postmarketing studies that agency ordered three manufacturers of duodenoscopes to conduct to assess bacterial contamination of devices.

FDA - U.S. Food and Drug Administration

20-10-2018

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of FGE.19 in the Flavouring Group Evaluation 200 Revision 1 (FGE.200 Rev1). In FGE.200, genotoxicity studies were provided for one representative substance, namely hex‐2(trans)‐enal [FL‐no: 05.073], and for other two substances in the same subgroup, namely 2‐dodecenal [FL‐no: 05.03...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Published on: Wed, 17 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to consider in this revision 2 of Flavouring Group Evaluation 201, the additional data on genotoxicity submitted by the Industry on two substances, 2‐methylpent‐2‐enal [FL‐no: 05.090] and 2 methylcrotonaldehyde [FL‐no: 05.095], from subgroup 1.1.2 of FGE.19. In FGE.201Rev1, the Panel concluded that further data were required in order to clarify the genotoxic poten...

Europe - EFSA - European Food Safety Authority Publications

23-8-2018

The Manhattan Toy Company recalls Pull-Back Speedy Jets

The Manhattan Toy Company recalls Pull-Back Speedy Jets

The rubber tires can separate from the wheels posing a small parts choking hazard for small children.

Health Canada

20-6-2018

Bumbleride Inc recalls Bumbleride Speed 3-wheel jogging stroller

Bumbleride Inc recalls Bumbleride Speed 3-wheel jogging stroller

Health Canada's sampling and evaluation program has determined that this jogging stroller does not meet the sharp edge requirements of the Carriages and Strollers Regulations in Canada. The metal edge of the back hinge located on the right side of the jogging stroller can be sharp, posing a potential risk of cut or laceration.

Health Canada

14-12-2018

#ICYMI: Jeff Shuren, Director of the Center for Devices & Radiological  Health, released a statement on updated safety  communication about  rates of duodenoscope contamination from  preliminary postmarket data.  Read the statement here:  https://go.usa.g

#ICYMI: Jeff Shuren, Director of the Center for Devices & Radiological Health, released a statement on updated safety communication about rates of duodenoscope contamination from preliminary postmarket data. Read the statement here: https://go.usa.g

#ICYMI: Jeff Shuren, Director of the Center for Devices & Radiological Health, released a statement on updated safety communication about rates of duodenoscope contamination from preliminary postmarket data. Read the statement here: https://go.usa.gov/xE3kf  #MedicalDevice

FDA - U.S. Food and Drug Administration

10-12-2018

.@US_FDA is emphasizing the importance of manual cleaning prior to disinfection or sterilization and proper servicing of duodenoscopes. Read more:  https://go.usa.gov/xPShF  #MedicalDevice #FDApic.twitter.com/HiJbgPnsPt

.@US_FDA is emphasizing the importance of manual cleaning prior to disinfection or sterilization and proper servicing of duodenoscopes. Read more: https://go.usa.gov/xPShF  #MedicalDevice #FDApic.twitter.com/HiJbgPnsPt

. @US_FDA is emphasizing the importance of manual cleaning prior to disinfection or sterilization and proper servicing of duodenoscopes. Read more: https://go.usa.gov/xPShF  #MedicalDevice #FDA pic.twitter.com/HiJbgPnsPt

FDA - U.S. Food and Drug Administration

29-10-2018

DuoPlavin (Sanofi Clir SNC)

DuoPlavin (Sanofi Clir SNC)

DuoPlavin (Active substance: clopidogrel / acetylsalicylic acid) - Centralised - 2-Monthly update - Commission Decision (2018)7255 of Mon, 29 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1143/WS/1433/0050

Europe -DG Health and Food Safety

2-10-2018

Xigduo (AstraZeneca AB)

Xigduo (AstraZeneca AB)

Xigduo (Active substance: dapagliflozin/metformin) - Centralised - Renewal - Commission Decision (2018)6462 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2672/R/44

Europe -DG Health and Food Safety

22-7-2018

We'll consider regulatory options to speed up requiring companies to mitigate safety problems identified postmarket. Currently, mitigations such as new user training or new labeling can require rulemaking, which takes time and resources

We'll consider regulatory options to speed up requiring companies to mitigate safety problems identified postmarket. Currently, mitigations such as new user training or new labeling can require rulemaking, which takes time and resources

We'll consider regulatory options to speed up requiring companies to mitigate safety problems identified postmarket. Currently, mitigations such as new user training or new labeling can require rulemaking, which takes time and resources

FDA - U.S. Food and Drug Administration

5-6-2018

DuoTrav (Novartis Europharm Limited)

DuoTrav (Novartis Europharm Limited)

DuoTrav (Active substance: Travoprost / Timolol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3622 of Tue, 05 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/665/T/53

Europe -DG Health and Food Safety